IL230758A0 - Folate conjugates of albumin-binding entities - Google Patents

Folate conjugates of albumin-binding entities

Info

Publication number
IL230758A0
IL230758A0 IL230758A IL23075814A IL230758A0 IL 230758 A0 IL230758 A0 IL 230758A0 IL 230758 A IL230758 A IL 230758A IL 23075814 A IL23075814 A IL 23075814A IL 230758 A0 IL230758 A0 IL 230758A0
Authority
IL
Israel
Prior art keywords
albumin
binding entities
folate conjugates
folate
conjugates
Prior art date
Application number
IL230758A
Other languages
Hebrew (he)
Other versions
IL230758B (en
Original Assignee
Merck & Cie
Merck Eprova Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Cie, Merck Eprova Ag filed Critical Merck & Cie
Publication of IL230758A0 publication Critical patent/IL230758A0/en
Publication of IL230758B publication Critical patent/IL230758B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
IL230758A 2011-08-17 2014-01-30 Folate conjugates of albumin-binding entities, pharmaceutical composition comprising the same and method for diagnostic imaging of a cell or population of cells expressing a folate‐receptor IL230758B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11177732 2011-08-17
PCT/EP2012/065702 WO2013024035A1 (en) 2011-08-17 2012-08-10 Folate conjugates of albumin-binding entities

Publications (2)

Publication Number Publication Date
IL230758A0 true IL230758A0 (en) 2014-03-31
IL230758B IL230758B (en) 2020-11-30

Family

ID=46650547

Family Applications (1)

Application Number Title Priority Date Filing Date
IL230758A IL230758B (en) 2011-08-17 2014-01-30 Folate conjugates of albumin-binding entities, pharmaceutical composition comprising the same and method for diagnostic imaging of a cell or population of cells expressing a folate‐receptor

Country Status (11)

Country Link
US (1) US9295739B2 (en)
EP (1) EP2766364A1 (en)
JP (1) JP6152104B2 (en)
KR (1) KR102036199B1 (en)
CN (1) CN103732595B (en)
AU (1) AU2012296937B2 (en)
CA (1) CA2839647C (en)
EA (1) EA201400237A1 (en)
IL (1) IL230758B (en)
WO (1) WO2013024035A1 (en)
ZA (1) ZA201400174B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103732563B (en) * 2011-08-22 2016-04-20 默克及其合伙人公司 18f-sugar-folic acid class
CN104897627B (en) * 2015-02-04 2017-07-11 浙江工商大学 A kind of method of the fluoroscopic examination folic acid based on molecular recognition
WO2016168471A1 (en) * 2015-04-17 2016-10-20 Endocyte, Inc. Dual disulfide drug conjugates
WO2017040963A1 (en) 2015-09-03 2017-03-09 Forma Therapeutics, Inc. [6,6] fused bicyclic hdac8 inhibitors
JP2019515880A (en) 2016-03-16 2019-06-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． Carbonic anhydrase IX inhibitor conjugates and uses thereof
JP7027325B2 (en) 2016-03-16 2022-03-01 パーデュー・リサーチ・ファウンデイション Drugs and methods targeting carbonate anhydrous enzyme IX
CA3030907A1 (en) * 2016-08-10 2018-02-15 Cancer Targeted Technology Llc Chelated psma inhibitors
CN117563022A (en) * 2017-04-05 2024-02-20 康奈尔大学 Trifunctional constructs with tunable pharmacokinetics for imaging and anti-tumor therapy
CN110740757B (en) 2017-05-24 2023-04-04 同位素技术慕尼黑公司 Novel PSMA-binding agents and uses thereof
WO2018233798A1 (en) 2017-06-20 2018-12-27 ITM Isotopen Technologien München AG Novel psma-binding agents and uses thereof
US20200276338A1 (en) * 2017-09-19 2020-09-03 The Governors Of The University Of Alberta Bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their applications in multimodal theranostic management of hypoxia diseases including cancer
CN112409436B (en) * 2020-11-06 2022-02-18 厦门大学 Radionuclide-labeled estrogen receptor molecule targeting compound and application thereof
WO2024025845A1 (en) * 2022-07-25 2024-02-01 Sorrento Therapeutics, Inc. Folate-conjugated drugs and uses thereof
WO2024051794A1 (en) * 2022-09-09 2024-03-14 同宜医药（苏州）有限公司 Radionuclide-drug conjugate and pharmaceutical composition and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136159A (en) 1977-02-28 1979-01-23 New England Nuclear Corporation Radioassay of folates
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5919934A (en) 1997-02-19 1999-07-06 The George Washington University Compounds, compositions, and methods for cancer imaging and therapy
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
SI2151250T1 (en) 2002-05-06 2014-02-28 Endocyte, Inc. Vitamin-Targeted imaging agents
WO2003101972A1 (en) 2002-05-30 2003-12-11 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
KR20080000620A (en) 2005-04-27 2008-01-02 지멘스 메디컬 솔루션즈 유에스에이, 인크. Click chemistry method for synthesizing molecular imaging probes
CA2625196C (en) * 2005-10-07 2016-04-05 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
FR2891830B1 (en) * 2005-10-07 2011-06-24 Guerbet Sa SHORT AMINOALCOHOL COMPOUNDS AND METAL COMPLEXES FOR MEDICAL IMAGING
KR101639268B1 (en) * 2007-04-11 2016-07-13 메르크 앤드 씨에 18 f-labelled folates
EA200901344A1 (en) * 2007-04-11 2010-04-30 Мерк Эпрова Аг FOLAT CONJUGATES AND RELATED METAL CHELATE COMPLEXES FOR APPLICATION FOR DIAGNOSTIC VISUALIZATION AND RADIOTHERAPY
CA2708171C (en) 2007-12-04 2018-02-27 Alnylam Pharmaceuticals, Inc. Folate conjugates

Also Published As

Publication number Publication date
CN103732595B (en) 2017-02-08
KR102036199B1 (en) 2019-10-24
ZA201400174B (en) 2015-09-30
AU2012296937B2 (en) 2017-10-12
JP6152104B2 (en) 2017-06-21
US9295739B2 (en) 2016-03-29
CA2839647A1 (en) 2013-02-21
EP2766364A1 (en) 2014-08-20
US20140234216A1 (en) 2014-08-21
CN103732595A (en) 2014-04-16
CA2839647C (en) 2022-08-16
IL230758B (en) 2020-11-30
AU2012296937A1 (en) 2014-02-20
EA201400237A1 (en) 2014-08-29
KR20140052027A (en) 2014-05-02
JP2014531407A (en) 2014-11-27
WO2013024035A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
HRP20190576T1 (en) Methods of preparation of conjugates
IL263973B (en) Protein-polymer-drug conjugates
HRP20180646T1 (en) Dispiropyrrolidine derivative
IL230758A0 (en) Folate conjugates of albumin-binding entities
HK1196257A1 (en) P97-antibody conjugates p97-
IL228404A0 (en) Anitbody-drug conjugates
IL247639B (en) Heteroarylpiperidine derivatives
EP2683400A4 (en) Listeria-based adjuvants
IL231950B (en) Aryl-quinoline derivatives
EP2721029A4 (en) Imidazopyridin-2-one derivatives
EP2687531A4 (en) Tetrahydrocarboline derivative
EP2740730A4 (en) Dibenzooxepin derivative
IL233001A0 (en) Novel iso-ergoline derivatives
SI2766342T1 (en) Phenyl-guanidine derivatives
EP2684869A4 (en) Preparation of 3-mercaptopropionates
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
GB201102913D0 (en) Novel therapeutic
IL210721A0 (en) Joint mechanism
IL229109A0 (en) Diognosis of cancer
GB2552754B (en) Methods of positioning toilet components
HUE036665T2 (en) Solid form of dihydro-pyrido-oxazine derivative
ZA201209319B (en) Cyclopropyl-indole derivatives
GB201109614D0 (en) Odontalgic preparation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed